Intravenous Infusions is trading at GHS 0.48 (-9.43%) as profit-taking continues after a speculative rally that peaked at GHS 0.86 on July 30.
- Selling pressure follows several consecutive declines
- First-half revenue fell 39%, despite improved margins and a return to profitability
- No new company announcement dated August 12, 2026 was identified; latest reporting attributes the decline to profit-taking